MU RESEARCHERS SEARCH FOR CAUSES AND POSSIBLE CURES FOR RHEUMATOID ARTHRITIS WITH $1.1 MILLION NIH GRANT

Sept. 24, 1999
Contact: Teressa Tignor Gilbreth
Information Specialist
(573) 882-9144
GilbrethT@missouri.edu



COLUMBIA, Mo. -- There is new hope for the 2.1 million people in the United States who suffer from the painful, chronic disease of the joints, rheumatoid arthritis. With the help of a five-year $1.1 million grant from the National Institutes of Health, two researchers from the University of Missouri-Columbia College of Veterinary Medicine are searching for the causes of and possible cures for the crippling disease.

Bimal Ray, an associate professor of veterinary pathobiology; and his co-investigator and wife, Alpana Ray, an assistant research professor; have been working for 10 years on research related to serum amyloid A (SAA), the protein they believe is a key trigger for rheumatoid arthritis and a host of other diseases.

Rheumatoid arthritis inflames and thickens the tissues that line the joints, most commonly the small joints of the hands, causing pain and swelling. Researchers had given up hope for a cure for the disease until recent discoveries in cellular biology and immunology brought new hope.

With clues from their current study, the Rays hope to identify the process that causes rheumatoid arthritis, design pharmaceutical treatments to stop it and investigate possible connections to cardiovascular disease, diabetes, osteoarthritis and other diseases.

"We've found the link between these diseases, and now we're trying to identify it and prove it is true," Alpana Ray said.

"Identifying the mechanism of the inflammation is our focus on this study," Bimal Ray said. Although they are using animal tissue culture cells and gene cloning to study inflammation, he said the research is geared toward human disease.

Current treatment strategies for rheumatoid arthritis include pain relief through medication, rest and exercise, patient education, support programs and in some cases surgery. One possible avenue of the new research is to control the disease process by simply limiting SAA production and its related actions in the joints.

If initial research proves successful, they could begin testing an experimental treatment for rheumatoid arthritis in five to 10 years, Bimal Ray said.
 


 

 

DISCLAIMER:

The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website.  Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use.  The International Still's Disease Foundation is a non-profit organization.   This page was last updated on June 13, 2002

Copyright© 1999-2002 International Still's Disease Foundation